



The Present and Future Prospectives of Pharmacovigilance

Martha Srinivas*, Jatroth Santhosh¹, Kavali Swetha²

*Associate Professor, Department of Pharmaceutics, Joginpally B.R. Pharmacy College, Yenkapally (V), Moinabad (M), Hyderabad-75, Telangana, India.

^{1,2}Department of Pharmaceutical sciences, Joginpally B.R. Pharmacy College, Yenkapally (V), Moinabad (M), Hyderabad-75, Telangana, India.

*Corresponding author's E-mail: srinivaaspharma@gmail.com

Received: 22-11-2022; Revised: 25-01-2023; Accepted: 31-01-2023; Published on: 15-02-2023.

ABSTRACT

Pharmacovigilance assumes a significant part in the medical care framework through checking and connection of medications and there impacts in the human body. The number of Unfavorable Medication Responses (ADRs) detailed and to comprehend the pharmacovigilance, an elevated degree of mastery is expected to quickly identify drug gambles too as to shield the item against an improper evacuation. The ongoing worldwide organization of pharmacovigilance focuses, composed by the Uppsala Observing Center, would be fortified by a free arrangement of survey. Prescriptions wellbeing checking is a nonstop and dynamic interaction all through every one of the periods of the life pattern of a medication. In the field of medication wellbeing and guideline, various difficulties must be looked in the close future. Above all else, Coronavirus pandemic featured how applicable pharmacovigilance and appropriate risk correspondence during general wellbeing crisis are. Systems including AI methods and the accessibility of enormous measure of electronic medical care information offer an open door for streamlining drug benefit-risk profile assessment in genuine world setting. At last, creative therapeutics, like high level treatment restorative items, computerized therapeutics, antibodies created in light of trend setting innovations, requiring exceptional pharmacovigilance checking have been progressively showcased as of late, frequently upon sped up pathway endorsement. A portion of the difficulties and future open doors in this field are momentarily talked about beneath. Regulatory authorities, ethics committees, and pharmaceutical and biopharmaceutical businesses are now mandated to be interested in drug safety monitoring. ADRs account for 10% or more of hospitalizations in several nations. Additionally, 10–20% of hospital inpatients are thought to experience ADRs. The only truly effective means of ensuring the public's health is through appropriate and efficient ADR monitoring, or pharmacovigilance. The goal and methodology of pharmacovigilance were outlined in this article along overview of how it is currently practiced in India, its difficulties, and its prospects for the future. The principal objective of pharmacovigilance is subsequently to advance the protected and viable utilization of wellbeing items, specifically by giving ideal data about the security of wellbeing items to patients, medical services experts, and people in general. Pharmacovigilance is hence an action adding to the assurance of patients and keeping up with general wellbeing.

Keywords: Pharmacovigilance, Regulation of pharmacovigilance, fundamental of pharmacovigilance, drug safety, departments of pharmacovigilance.

QUICK RESPONSE CODE →

DOI:

10.47583/ijpsrr.2023.v78i02.013



DOI link: <http://dx.doi.org/10.47583/ijpsrr.2023.v78i02.013>

of England died after receiving chloroform anesthetic before removal of an infected toenail. Sir James Simpson had discovered that chloroform was a safer and powerful anesthetic, and he had introduced it in clinical practice. The causes of Hannah's death were investigated to understand what happened to Hannah, but it was impossible to identify what killed her. Probably she died of a lethal arrhythmia or pulmonary aspiration.⁶⁻⁸

INTRODUCTION

Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine/vaccine related problem.¹⁻²

'Pharmacovigilance' is a combination of two words, the Greek Pharma on, meaning 'drug', 'medicine' and the Latin vigil are, 'keep awake'.³⁻⁵

History of Pharmacovigilance

Pharmacovigilance started about 170 years ago, although it was not yet named as such at that time. On Jan 29, 1848, when a young girl named Hannah Greener from the North

The origin of pharmacovigilance in India goes back to 1982, when a formal adverse drug reaction (ADR) monitoring system consisting of 12 regional centers, each covering a population of 50 million, was proposed for India. India decided to join the Uppsala Centre for adverse event monitoring. Pharmacovigilance aims at withdrawal of the regulatory agencies and media. Also, consumers have become more aware about the benefit and risks of medicines.⁹⁻¹⁰



1 Different Types of Departments in Pharmacovigilance




Figure 1: Departments of Pharmacovigilance




Figure 2: Pharmacovigilance departments' components

Limitations of Pharmacovigilance

Reports in medical journals about the suspected adverse effects are an established way to alert about drug hazards. These reports are one of the signal generating reports easily accessible by the general population.¹¹⁻¹³ Limitations in these include:

1. A small number of cases are published.
2. Delay in occurrence and publication of adverse event
3. Reports are poorly documented.

2 Regulations of Pharmacovigilance

Pharmacovigilance programs made strong by links with regulators. Regulators understand that pharmacovigilance plays a specialized and pivotal role in ensuring ongoing safety of medicinal products.¹⁴⁻¹⁵

a. Clinical trial regulation

Clinical trials have significantly increased in both industrialized and developing nations in recent years. Regulatory organization considers the safety and efficacy of novel products under investigation before approving

clinical trials. Clinical trials have significantly increased in both industrialized and developing nations in recent years. Regulatory organizations consider the safety and effectiveness of novel goods under investigation before approving clinical trials.¹⁶⁻¹⁸

b. Post marketing safety drug monitoring

These include monitoring the negative effects on human health of drug residues in animals, such as antibiotics and hormones, and measuring the environmental burden of medicines used by large populations. They also include systems for comparing the safety profiles of similar medicines and the detection of drug interactions. The benefit-risk assessment of medications following their marketing as reported by the Council for International Organizations of Medical Sciences (CIOMS) has aided in the development of a more methodical evaluation process for drugs that are currently on the market.¹⁹⁻²¹

c. Pharmacovigilance in national drug Policy

The arrangement of good quality protected and compelling medications and their suitable use is the obligation of public legislatures. Multidisciplinary cooperation is vital specifically, joins should be manufactured between different branches of the service of wellbeing and furthermore with different partners, like the drug business, colleges, nongovernmental associations (NGOs) and those expert affiliations having liability regarding training on reasonable utilization of prescriptions and pharmacotherapy checking.²²⁻²⁴

d. Pharmacovigilance in Disease Control Public Health Programs

The observing of medication security in nations where there is no administrative or wellbeing checking framework set up, or in far off regions with practically no medical care reconnaissance or foundation, has been distinguished as an issue for concern.²⁵

3. Fundamental concepts of pharmacovigilance

Argus Safety. Argus Wellbeing is Prophet's finished pharmacovigilance programming framework intended to settle the drug business' hardest administrative difficulties. Argus Wellbeing upholds drug security business processes from a straightforward UI.²⁶⁻²⁷

Adverse Event: An unfriendly occasion (AE) is any undesirable clinical event a consuming a restorative in a patient item. This event doesn't be guaranteed to must have a causal relationship with this treatment. An unfriendly occasion can consequently be any negative and accidental sign (for instance, a strange research facility finding), side effect, or sickness transiently connected with the utilization of a restorative item, whether thought about connected with this restorative item.²⁸⁻³⁰

Adverse Drug Reaction: All poisonous and accidental reactions to a restorative item connected with any portion are viewed as unfriendly medication responses. The expression "reactions to a restorative item" implies that a

causal connection between a therapeutic item and an unfriendly occasion is basically a chance. The distinction among AE and ADR is that an ADR is portrayed by the way that a causal connection among drug and the event is thought yet it isn't required in the event of an AE.³¹⁻³²

Seriousness, Expectedness and Relatedness: ICH E2A rule says that a "Serious" AE or ADR is any horrible clinical event that at any portion:

All AEs that are already unnoticed or undocumented are classified "unforeseen". Their tendency or seriousness isn't predictable with the pertinent item data (e.g., Specialist's Leaflet for an unapproved investigational restorative item). Assurance of expectedness is made by the support dependent upon the situation. Expected occasions regularly don't need sped up answering to the administrative specialists. "Relatedness" or "Causality Evaluation" implies that examination is finished to decide whether the occasion has a sensible chance of being connected with the utilization or openness to item. Many terms and scales are utilized to portray the level of causality, including terms, for example, positively, certainly, presumably, potentially, or probable related or not related, yet there is no norm.³³⁻³⁶

SUSAR: suspected unexpected serious Adverse Reaction

Product: A product can be of 3 types: Drug, Vaccine or Device (e.g. Syringe, Pacemaker). Following is product related information:

Product Generic Trade e.g. Product family can be Mute-Vitamins, Product group can be Nutritional Supplements, Generic Name can be Complex, Trade name can be Revit, and Ingredients can be Vitamin B1, B2, B3, B4, B6 and B12.³⁷⁻³⁸

Challenge-deciding e-challenge (CDR): Challenge-DE challenge-challenge (CDR) is a clinical testing convention wherein a medication or medication is controlled, removed, then redirected, while being observed for unfavorable impacts at each stage. The convention is utilized while measurable testing is unseemly because of a particular response by a particular individual, or an absence of adequate guinea pigs and unit of investigation is the person. During the pull out stage, the drug is permitted to clean out of the framework to figure out what impact the prescription is having on a person. CDR is one method for laying out the legitimacy and advantages of prescription in regarding explicit circumstances as well as any unfriendly medication responses. The Food and Medication Organization of the US records positive DE challenge responses (an unfriendly occasion which vanishes on withdrawal of the medicine) as well as bad (an unfavorable occasion which go on after withdrawal), as well as certain challenge (side effects re-happening on re-organization) and negative challenge (disappointment of a side effect to re-happen after re-organization).³⁹⁻⁴²

ICSR (Individual Case Safety Report): ICSR is a report of data portraying unfriendly event(s)/reaction(s)



experienced by a singular patient. The event(s)/reaction(s) can be connected with the organization of at least one restorative item at a specific moment. The ICSR can likewise be utilized for trade of other data, for example, medicine error(s) that don't include antagonistic events(s)/reaction(s). An ICSR may likewise be alluded to as Wellbeing Report.⁴³⁻⁴⁵

E2B (Electronic to Business): E2B is the global norm for communicating medication unfriendly occasion reports determined by the ICH.⁴⁶

MedDRA: Medical Dictionary for Drug Regulatory Affairs/Activities is a clinically approved worldwide clinical phrasing utilized by administrative specialists and the managed biopharmaceutical industry all through the whole administrative cycle, from pre-showcasing to post-promoting exercises, and for information passage, recovery, assessment, and show. Med DRA is utilized in the US, European Association and Japan. Its utilization is as of now commanded in Europe and Japan for wellbeing detailing.

The Med DRA dictionary is organized by System Organ Class (SOC), divided into High-Level Group Terms (HLGT), High-Level Terms (HLT), Preferred Terms (PT) and finally into Lower-Level Terms (LLT). In addition, the Med DRA dictionary includes Standardized Med DRA Queries (SMQs). SMQs are groupings of terms that relate to a defined medical condition or area of interest. WHO dictionary is used for products (drugs, vaccines or devices) while Madera is used for events (e.g. diagnosis, symptoms etc.)⁴⁷

Efficacy (of a medicine or treatment): The capacity of a medication or treatment to create an outcome. A medication passes viability preliminaries in the event that it is compelling at the portion tried and against the sickness for which it is recommended.

Marketing Authorization Application (MAA) —This is an EU expression and is an application to the important wellbeing authority inside the EU, for instance the European Drugs Organization, for endorsement to showcase a restorative item.

Marketing Authorization Holder (MAH) —This is an EU expression. The MAH is the organization in whose name the showcasing approval has been allowed. This party is answerable for all parts of the item, incorporating quality and consistence with the states of the showcasing approval.

New Drug Application (NDA)— This is a US expression. It is an application for a permit to showcase a medication for a predefined sign, submitted to the US FDA after clinical preliminaries have been finished.⁴⁸

Steps involved in Pharmacovigilance:

1. Support use of accredited Institutional Review Boards (IRBs). The course of deliberate certification can assist with normalizing best practices for the direct of human clinical preliminaries, guarantee a legitimate spotlight

on administrative consistence, and accomplish these and different advantages without expanding administrative weight. Consider, for instance, AAHRPP (the Relationship for the Certification of Human Exploration Security).⁴⁹

2. Timely register of human clinical trials in the federal Data Bank.

Congress expected the information bank to be an asset to work with patient enlistment in U.S. preliminaries testing the viability of medications for serious and perilous illness. The HHS Office of Controller General will concentrate on drug industry consistence, and FDA execution endeavors in 2005.⁵⁰

3. Attend to Phase IV study commitments. There are many authentic motivations behind why post-advertising studies are not finished in the time period at first consented to with the FDA. Yet, there can be repercussions for inability to finish concentrates on in an opportune design; the HHS Office of Overseer General likewise plans to refresh its survey of industry consistence around here during 2005.

4. Establish and implement company policy regarding the disclosure of clinical trial results.

New York Principal legal officer Eliot Spitzer demands that "another norm of exposure" has been laid out for industry to lay out an internet based register containing synopses of all preliminaries led beginning around 2000. Whether or not there is as a matter of fact "another norm," organizations need to choose whether and what to report, reliable with FDA naming and advancement commitments, as well as the SEC/FDA method that has been laid out for alluding supposedly "bogus and deluding" explanations to the SEC Division of Implementation.⁵¹

5. Recognize that there is a growing focus on post-approval review, and a changing role for both private and public payers like the Centers for Medicare & Medicaid Services (CMS).

There are changing ideas of non-routine dangers, with suggestions for keeping a medication's endorsement status despite recently accessible advantage/risk information. Further confusing the image is the arising job of CMS in supporting results exploration, and in any event, molding Federal health care installment for treatment on paying for (on account of medication supports) and partaking in (on account of patients) adequacy/result studies.

6. Anticipate the impact of negative trial results on indications, labeling and approval status.

A lot of is in question to start arranging what activities to take solely after regrettable human clinical preliminary outcomes become accessible. Confusing sound arranging is the way that any assertions, messages and notices concerning arising data will without a doubt be seen, and decided, looking back. Indeed, even the presentation of a later-age medication can have suggestions for the



proceeded with feasibility of the primary medication in a given helpful class (just like with the withdrawal of Sedan following FDA endorsement of a "more secure" elective, Allegra). There are likewise developing stakes for the two trend-setters, and generics, in the FDA's assurance of the explanations behind withdrawal under 21 C.F.R. §314.161.

7. Prepare Direct-To-Consumer (DTC) advertising programs to withstand further heightened scrutiny.

Late FDA directions have noticed the supportive of patient advantages of DTC (to invigorate specialist visits and patient mindfulness, and uncover already undiscovered circumstances). In any case, some have long scrutinized the appropriateness of such advertisements and other limited time exercises, which presently will be under reestablished pressure (e.g., whether promotions can fuel item obligation openness, especially where the FDA might have viewed them as bogus, ailing in balance, or misdirecting).

8. Stay current on evolving preemption law and policy.

The FDA has been progressively vocal in encouraging that government endorsement and naming choices seize state courts and juries, a pattern liable to go on during the subsequent Bramble term.

9. Continually update employees on changing standards, and the implications for your business.

Changing expectations at the FDA, and at other state and federal enforcement agencies, necessitate stepped-up continuing education at regulated companies. Employees need to appreciate the importance of their roles for public health (e.g., signal detection as adverse event and other information comes in), and for maintaining corporate compliance (the growing array of post-approval obligations, and the need to recognize that any communication whether paper or electronic must be taken seriously and may last virtually).

A. Role of pharmacy professional in pharmacovigilance:

The Drug store calling has encountered huge change over the last a few decades. Drug specialists can utilize Pharmacovigilance frameworks connected with electronic wellbeing records to notice the medications they fill and perceive unfavorable medication responses faster than non-drug specialists, in this manner diminishing costly medical care costs. Pharmacovigilance data frameworks oversaw by drug specialists can perceive unfavorable medication responses in arising nations where quality control of prescriptions is sketchy. Reports recommended that patients had lacking information about their endorsed drugs, despite the fact that they had been involving them for some time. 73% of drug specialists work in medical clinic or drug store settings, where they can confront occasions in view of unfavorable medication responses or other medication related issues. Their contribution in pharmacovigilance frameworks is vital. The improvement of electronic data frameworks has been an achievement in recognizing and mediating drug-related issues like

measurement, unfriendly responses, communications, consistence, or incapability. Such choice emotionally supportive networks in electronic clinical records can catch drug connections or recognize different issues (e.g., contraindications) with solutions before they are filled.

Drug specialists play a significant part in the US and wellbeing frameworks to keep up with the levelheaded and safe utilization of medicine, for they are drug specialists who are explicitly prepared in this field. They guarantee that the medications in the commercial center we consume are by and large protected, and every one of those distinguished as risky are removed the market. Pharmacovigilance is a magnificent business choice for clinical, drug store, and life science graduates. It has brought about drug specialists assuming on more noteworthy liability in overseeing minor sicknesses and conveying general wellbeing mediations. There is no restriction to the patients managed by drug specialists. Drug specialists can completely utilize their clinical capacities and generally include conclusion and restorative administration. Like never before previously, local area drug specialists are currently in a situation to recognize, record, and report prescription security occurrences.⁵¹

B. Role of pharmacovigilance in healthcare professional:

Medical services experts assume a vital part in the pharmacovigilance framework. He\ require extensive information and skill in the field of medicine security which will effectively add to this area through early acknowledgment, the executives, and revealing of the medication security issues. Besides, the medical care experts ought to be knowledgeable about the need and system of antagonistic occasion revealing. He\ ought to have a blend of preparing and research abilities around here. In spite of worldwide worries against medicine security, there is an absence of mindfulness and information on pharmacovigilance and ADR detailing among medical services experts yet. In addition, ongoing examinations have shown that ADRs are ineffectively announced by medical services suppliers, particularly in non-industrial nations. It has been accounted for that main 2-4% of all unfriendly responses and 10% of serious ADRs are accounted for around the world. It is exceptionally suggested that medical services experts including doctors, drug specialists, and medical attendants report any thought antagonistic response especially those thought responses to recently approved prescriptions furthermore, serious occasions. Hereford the medication security evaluation should be Unconstrained unfavorable response detailing is the fundamental spine of pharmacovigilance and is expected to make theories about potential damages of meds that need further assessment. Unconstrained revealing is exceptionally useful in distinguishing proof of extremely uncommon or deferred responses that couldn't be identified during the brief time of the clinical preliminary. He security of a medication could be examined Dyer its endorsement and all through its life cycle by utilizing unconstrained revealing. He information and



impression of medical care experts toward wellbeing profile of medications is fundamental. He\ ought to know about the possible event of surprising unfavorable responses and report thought antagonistic responses to the Medication Administrative Specialists to work with recognition and appraisal of medication security signals. Medical care expert ought to see that no therapeutic item is altogether or totally ok for all individuals, in all spots, consistently. He\ must continuously practice with some proportion of vulnerability.⁵²

C. Role of pharmacovigilance in pharmaceutical industry:

Job of Pharma Organization Around the world:

- Interest in Research and development of new builds
- Obligation to put up new medication for sale to the public to
- upgrade patients' wellbeing and personal satisfaction
- Severe administration to direct clinical preliminaries and
- item improvement exercises
- Direct relations with patients and medical services
- experts as per moral and legitimate standards.

Drug T wellbeing and hazard:

- The test of augmenting drug wellbeing and keeping up with public certainty has become progressively complicated.
- Drug and biotechnology organizations must screen, yet in addition proactively survey and oversee drug risk all through an item's lifecycle, from advancement to post market.⁵³

CONCLUSION

Pharmacovigilance keeps on assuming a critical part in meeting the difficulties presented by the always expanding range also, power of drugs, all of which convey an unavoidable also, some-times unusual potential for hurt. At the point when unfavorable impacts and poisonousness do show up, particularly at the point when already obscure, it is fundamental that these are detailed, broke down and their importance is imparted successfully to the crowd having information to decipher the data.

Pharmacovigilance takes a gander at all suitable data to survey the data to survey the medication. Pharmacovigilance ought to likewise take the advantage of the medication in account. Pharmacovigilance expected for deliberately distinguishing and relating medications and medications and y effects and taking remedial activities.

REFERENCES

1. Pip Asha,B.,Arun, K.B.,, Setting standards for proactive pharmacovigilance in India: The way forward", Indian J pharmacology, 2007; 39(3): 124-128.
2. Kumanan, R., Sudha, S., Vijayashre, P., Charumath, S., Gowridevi, K.C., Mahesh, M. Imperative Approach on pharmacovigilance in Indian systems of medicine. 2022.
3. Deepa, A. „ Pharmacovigilance obligations of the pharmaceutical companies in India", India J pharmacol, 2008; 40: S13-S16.
4. Zhengwu Lu. Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives", Drug, Health Care and patient safety, 2009; 1: 35-45. 5.
5. WHO, Pharmacovigilance: ensuring the safe use of medicines, Geneva: WHO 2004.
6. Edwards, A., Elwyn,G. „How should effectiveness of risk communication to aid patient's decision be judged", A review literature. Medical Decision Making 1999; 19(4): 128-434. 15.
7. Edwards, IR. „The accelerating need for pharmacovigilance", Journal of the Royal college of Physicians, 2009; 34: 48-51.
8. International Drug Monitoring: The Role of National Centers (WHO Technical Report Series No .498) WHO.
9. WHO, Definition of pharmacovigilance, 2002.
10. WHO Collaborating center for International Drug Monitoring: The importance of pharmacovigilance –Safety Monitoring of medicinal products: WHO publications, 2002.
11. Augustine, E. F., Adams, H. R., and Mink, J. W. Clinical Trials in Rare Disease: Challenges and Opportunities. J. Child. Neurol. 2013;28(9):1142–1150. doi:10.1177/0883073813495959.
12. Bazile, A. O., Yahir, A., and Tavonatti, N. P. Artificial Intelligence for Drug Toxicity and Safety. Trends Pharmacology. Sci. 2019;40(9):624–635. doe: 10.1016/tips. 2019.07.00.
13. Digital Therapeutics Alliance (2021). Understanding TX: A New Category of Medicine. Available at: <https://dtxalliance.org/understanding-dtx/>. (Accessed January 30, 2022).
14. European Medicines Agency (2021). Advanced Therapy Medicinal Products: Overview. Available at: <https://www.ema.europa.eu/en/human-regulatory/overview/advanced-therapy-medicinal-products-overview>.
15. European Medicines Agency. Summary of Risk Management Plan for Yescarta (Axicabtagene Ciloleucl). Available at: https://www.ema.europa.eu/en/documents/rmpsummary/yescarta-epar-risk-management-plan-summary_en.pdf. (Accessed January 30, 2022). European Medicines Agency (2018b).
16. Lane, J. C. E., Weaver, J., Kostka, K., Duarte-Salles, T., Abrahao, M. T. F., Alghoul, H., et al. PloS one, 2021;18(3):e0233885.
17. Risk of Hydroxychloroquine Alone and in Combination with Azithromycin in the Treatment of Rheumatoid Arthritis: a Multinational, Retrospective study The Lancet. Lancet Rheumatology. 2018;2(11):e698–e711. doi:10. 1016/S2665-9913(20)30276-9
18. Liu, M., Caputi, T. L., Dredze, M., Kesselheim, A. S., and Ayers, J. W. Internet Searches for Unproven COVID-19 Therapies in the United States. JAMA Intern. Med. 2020;180(8):1116–1118. doi:10.1001/jamainternmed.2020.1764
19. Williamson, E. J., Walker, A. J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C. E., et al. Factors Associated with COVID-19-Related Death Using OpenSAFELY. Nature 2020;584 (7821):430–436.



- doi:10.1038/s41586-020-2521-4
20. Food and Drug Administration (2019). FDA's Sentinel Initiative. Available at: <https://www.fda.gov/safety/fdas-sentinel-initiative>. (Accessed January 30, 2022).
 21. Singh, S., and Loki, Y. K. Drug Safety Assessment in Clinical Trials: Methodological Challenges and Opportunities. *Trials* 2012;13(138):13. doi:10.1186/1745-6215-13-138
 22. Geneva: World Health Organization. Looking at the Pharmacovigilance: ensuring the safe use of medicines. WHO Policy Perspectives on Medicines. Geneva: WHO; 2004. Available from: http://www.who.int/sq/2004/WHO_EDM_2004.8.pdf. [cited on 2009 Dec 15].
 23. Harmark L, van Grootheest AC. Pharmacovigilance: Methods, recent developments and future perspectives. *Euro J Clin Pharmacol* 2008; 64:743-52.
 24. Biswas P, Biswas A. Setting standards for proactive pharmacovigilance in India: The way forward. *Indian J Pharmacology*, 2007; 39:124-8.
 25. Coulter DM. The New Zealand intensive medicines monitoring programmed in proactive safety surveillance. *Pharmacoepidemiol Drug Saf* 2000; 9:273-80.
 26. Mackay FJ. Post-marketing studies: The work of the drug safety research unit. *Drug Saf* 1998; 19:343-53.
 27. Folb PI, ten Ham M. Drug monitoring in developing countries: A drug regulator's perspective. *Drug Inf J* 1995; 29:303-5.
 28. Talbot JC, Nilsson BS. Pharmacovigilance in the pharmaceutical industry. *Br J Clin Pharmacol* 1998; 45:427-31.
 29. Moore N. The role of the clinical pharmacologist in the management of ADRs. *Drug Saf* 2001; 24:1-7.
 30. Hall M, McCormack P, Arthurs N, Feely J. The spontaneous reporting of ADRs by nurses. *Br J Clin Pharmacol* 1995; 40:173-5.
 31. Hornbuckle K, Wu HH, Fung MC. Evaluation of spontaneous adverse event reports by primary reporter: A 15-year review (1983 to 1997). *Drug Inf J* 1999; 33:1117-24.
 32. Almandil N. B. Healthcare professionals' awareness and knowledge of adverse drug reactions and pharmacovigilance. *Saudi medical journal*, 2016;37(12): 1359-1364.
 33. Alwhaibi, M., & Al Aloola, N. A. Healthcare students' knowledge, attitude and perception of pharmacovigilance: A systematic review. *PloS one*, 2020;15(5):e0233393.
 34. Bagheri, H., Laroche, M. L., & Montastruc, J. L. Pharmacovigilance: The new challenges. *Therapie*, 2016;71(2):121–122.
 35. Diesel, G., & Cooles, S. Annual review of pharmacovigilance. *The Veterinary record*, 2018;183(2):72-75.
 36. Donzanti B. A. Pharmacovigilance is Everyone's Concern: Let's Work It Out Together. *Clinical therapeutics*, 2018;40(12):1967–1972.
 37. Hartman, J., Härmark, L., & van Puijenbroek, E. A global view of undergraduate education in pharmacovigilance. *European journal of clinical pharmacology*, 2017;73(7):891–899.
 38. Inacio, P., Cavaco, A., & Airaksinen, M. The value of patient reporting to the pharmacovigilance system: a systematic review. *British journal of clinical pharmacology*, 2017;83(2): 227–246.
 39. Kalaiselvan, V., Srivastava, S., Singh, A., & Gupta, S. K. Pharmacovigilance in India: Present Scenario and Future Challenges. *Drug safety*, 2019;42(3):339–346.
 40. Lihite, R. J., & Lahkar, M. An update on the Pharmacovigilance Programmed of India. *Frontiers in pharmacology*, 2015;6:194.
 41. Martin, L. G., Hanssens, Y., & Paudyal, V. Overview of this issue: pharmacovigilance, what is new? *International journal of clinical pharmacy*, 2018;40(4):737–739.
 42. 1. World health organization collaborating centre for international drug monitoring. The importance of pharmacovigilance available at http://www.who_umc.org cited 18 December 2007.
 43. Lazarou J, Pomeranz BH, Corey PN; Incidence of Adverse Drug Reactions in hospitalized patients. *JAMA*, 2020;279: 1200-1205.
 44. Bord CA, Rachi CL; Adverse Drug Reactions in United States Hospitals. *Pharmacotherapy*, 2006; 26(5): 601-08.
 45. World Health Organization (WHO), Uppsala Monitoring Centre(internet). The use of WHO-UMC system for standard case causality assessment available at <http://www.whoumc.org/graphics/4409>.
 46. Arimone Y, Begnad B, Miremont, Salame G, Fourrier-Regalt A, Moore N, Molimard M et al, agreement of expert judgment in causality assessment of adverse drug reactions. *Eur J Clin pharmacology*, 2005; 61: 169-173
 47. Moore N. The role of clinical pharmacologist in management of ADRs. *Drug safety*, 2001;211(1): 1-7.
 48. 1. The importance of pharmacovigilance; safety monitoring of medical products, Geneva, WHO, 2002.
 49. J.P Loannidis, J Lau. Completeness of safety reporting in randomized trials: an evaluation of seven medical areas. *JAMA*, 2001; 285(4): 437-443.
 50. P. Biswas, A. K. Biswas setting standards for proactive pharmacovigilance in India: the way forward. *Indian Journal of pharmacology*, 2007; 39: 124-128.
 51. Moore N. The role of clinical pharmacologist in the management of ADRs. *Drug safety*, 2001; 24(1): 1-7.

Source of Support: The author(s) received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

For any questions related to this article, please reach us at: globalresearchonline@rediffmail.com

New manuscripts for publication can be submitted at: submit@globalresearchonline.net and submit_ijpsrr@rediffmail.com

